Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Myths and realities of Medicare bidding program for durable medical equipment

Providers of home medical equipment and services across California are proposing a fiscally responsible alternative to the mislabeled "competitive" bidding scheme currently under way in Medicare that will actually discourage competition, reduce access to care for many of California's 4.6 million Medicare beneficiaries, and put thousands of California homecare providers out of business.

7 Aug 2010

Research Roundups: Expanding Medicaid; More spending doesn't reduce mortality; Colonoscopy cost effectiveness; Kids, asthma and access to care

Health Affairs: Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality - This study examines differences in hospital mortality and cost between 2000 and 2004 for patients at 122 U.S. hospitals, with seven common medical diagnoses: acute myocardial infarction, chronic obstructive pulmonary disease, community-acquired pneumonia, congestive heart failure, cerebrovascular accident (also called ischemic stroke), sepsis, or urinary tract infection.

7 Aug 2010

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States.

5 Aug 2010

Penn. effort fades to override cuts to family planning; Ill. faces budget cuts to health care; Mich. focuses on high cost of chronic disease

The Philadelphia Inquirer: "As two Democratic state lawmakers initiated a campaign to override the governor's veto of $7.5 million for family-planning health centers, six Republican state senators who previously voted to restore the funding reversed course, most likely ending any hopes of restoring the money. Democrats would need at least four Republican votes for an override in the Senate, which now appears unlikely.

5 Aug 2010

Foreign doctors provide care as good as that of Americans, study finds

Physicians trained in other countries provide care just as good as -- and perhaps better than some U.S. doctors, a report published in the journal Health Affairs found.

4 Aug 2010

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

Geron second-quarter net loss decreases to $17.0 million

Geron Corporation today reported financial results for the three and six months ended June 30, 2010.

30 Jul 2010

Response Biomedical closes $8 million common share private placement

Response Biomedical Corporation announced today that it has closed its previously announced private placement of common shares for gross proceeds of approximately $8 million. The Company issued 13,333,333 common shares at a price of C$0.60 per share.

29 Jul 2010

What steps should be taken when medicine can't save a life?

Writing for The New Yorker, Atul Gawande explores the central medical issues involved in treating patients with terminal conditions. He asks the question: "[I]f you were the one who had metastatic cancer—or, for that matter, a similarly advanced case of emphysema or congestive heart failure—what would you want your doctors to do? The issue has become pressing, in recent years, for reasons of expense.

28 Jul 2010

Response Biomedical announces shareholder approval for $8 million private placement

Response Biomedical Corporation announced that at the Company's Special General Shareholders' Meeting held today in Vancouver, shareholders approved the private placement of an aggregate of 13,333,333 common shares, at a price of Cdn. $0.60 per Offered Share, to Caduceus Private Investments III, LP, OrbiMed Associates III, LP and Caduceus Asia Partners, LP for gross proceeds of approximately Cdn. $8 million.

28 Jul 2010

Insurers test at-home technology, monitoring devices to help cut heart failure hospitalizations

Technology that aims to keep congestive heart failure patients out of the hospital is gaining traction. The idea is for heart patients to take readings like their weight, blood pressure and other key metrics using wireless and other technologies; the data are then transmitted to a case manager or medical care giver.

28 Jul 2010

Boehringer Ingelheim announces European CHMP Positive Opinion for TWYNSTA

Boehringer Ingelheim announced today that the European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA®. It will be indicated in adults whose blood pressure is not adequately controlled on amlodipine and is also indicated as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of TWYNSTA containing the same component doses.

26 Jul 2010

Ohio sets up high risk pool; Four drug companies come under scrutiny for payments to Pittsburgh doctors, nurses

"Ohioans with pre-existing health conditions, such as cancer or diabetes, can apply for coverage under a new high-risk insurance pool beginning Aug. 1." Qualifications include evidence of a pre-existing condition, proof of Ohio residency and U.S. citizenship, state of being uninsured for six months prior to the date of applying for coverage and being "ineligible for coverage under the Medicare program, the Ohio Medical Assistance Program, the Ohio Children's Health Insurance Program, or an employer-sponsored group health plan, unless subject to a mandatory initial waiting period" (7/22).

26 Jul 2010

Study reveals link between allergies, asthma and old age

Mistaken for illnesses like bronchitis and emphysema, exacerbated by medications like aspirin, and overlooked by patients and doctors alike, asthma is a common and highly treatable condition in older adults. And while allergies tend to decrease with age, they also are frequently disregarded as a potential cause of misery for the elderly.

23 Jul 2010

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

21 Jul 2010

GE Capital serves as sole lender to Mitralign for $5 million senior secured credit facility

GE Capital, Healthcare Financial Services announced today that it served as agent and sole lender to Mitralign, Inc. for a $5 million senior secured credit facility. Mitralign will use the credit facility for working capital as the company advances development of its mitral valve repair device.

19 Jul 2010

First Edition: July 19, 2010

Today's headlines include the latest news regarding the politics of implementing health reform as well as developments from the international AIDS conference now underway in Vienna.

19 Jul 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental New Drug Application for SPRYCEL (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.

12 Jul 2010

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

7 Jul 2010

Congestive Heart Failure News and Research

Myths and realities of Medicare bidding program for durable medical equipment

Research Roundups: Expanding Medicaid; More spending doesn't reduce mortality; Colonoscopy cost effectiveness; Kids, asthma and access to care

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Penn. effort fades to override cuts to family planning; Ill. faces budget cuts to health care; Mich. focuses on high cost of chronic disease

Foreign doctors provide care as good as that of Americans, study finds

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Geron second-quarter net loss decreases to $17.0 million

Response Biomedical closes $8 million common share private placement

What steps should be taken when medicine can't save a life?

Response Biomedical announces shareholder approval for $8 million private placement

Insurers test at-home technology, monitoring devices to help cut heart failure hospitalizations

Boehringer Ingelheim announces European CHMP Positive Opinion for TWYNSTA

Ohio sets up high risk pool; Four drug companies come under scrutiny for payments to Pittsburgh doctors, nurses

Study reveals link between allergies, asthma and old age

Genentech disappointed with FDA ODAC's recommendation against Avastin

GE Capital serves as sole lender to Mitralign for $5 million senior secured credit facility

First Edition: July 19, 2010

MD Buyline identifies top emerging technologies with highest impact

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News